Evidence map›Paper›PMID 28278078›Full record

ArticleCancer biology & therapy2017

Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.

Afia Muhammad Akram, Zafar Iqbal, Tanveer Akhtar, Ahmed Mukhtar Khalid, Muhammad Farooq Sabar, Mahmood Hussain Qazi, Zeba Aziz, Nadia Sajid, Aamer Aleem, Mahmood Rasool and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Chronic Myeloid Leukemia and the T315IInternational journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. A Retrospective Analysis ofSouth Asian journal of cancer · 2024
    Article
  5. The Oncobiome in Gastroenteric and Genitourinary Cancers.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Afia Muhammad Akrama Institute of Molecular Biology and Biotechnology, The University of Lahore , Lahore , Pakistan.
Zafar Iqbalb Hematology Oncology and Pharmacogenetic Engineering Sciences (HOPES) Group, Health Sciences Research Laboratories , Department of Zoology, University of the Punjab , Lahore , Pakistan.
Tanveer Akhtarb Hematology Oncology and Pharmacogenetic Engineering Sciences (HOPES) Group, Health Sciences Research Laboratories , Department of Zoology, University of the Punjab , Lahore , Pakistan.
Ahmed Mukhtar Khalida Institute of Molecular Biology and Biotechnology, The University of Lahore , Lahore , Pakistan.
Muhammad Farooq Sabard Centre for Applied Molecular Biology (CAMB), University of the Punjab , Lahore , Pakistan.
Mahmood Hussain Qazia Institute of Molecular Biology and Biotechnology, The University of Lahore , Lahore , Pakistan.
Zeba Azize Department of Oncology , Hameed Latif Hospital , Lahore , Pakistan.
Nadia Sajidf Department of Hematology and Oncology , Institute of Nuclear Medicine and Oncology , Lahore , Pakistan.
Aamer Aleemg College of Medicine and King Khalid University Hospital, King Saud University , Riyadh , Saudi Arabia.
Mahmood Rasoolh Centre of Excellence in Genomic Medicine Research, King Abdulaziz University , Jeddah , Saudi Arabia.
Muhammad Asifi Department of Biotechnology , Office of Research Innovation and Commercialization, Balochistan University of Information Technology, Engineering and Management Sciences , Quetta , Pakistan.
Saleh Aloraibij College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, National Guard- Health Affairs , Riyadh , Saudi Arabia.
Khaled Aljamaank Division of Pediatric Hematology/Oncology, Department of Oncology/King Saud Bin Abdulaziz University for Health Sciences , King Abdulaziz Medical City, National Guard Health Affairs , Riyadh , Saudi Arabia.
Mudassar Iqbalb Hematology Oncology and Pharmacogenetic Engineering Sciences (HOPES) Group, Health Sciences Research Laboratories , Department of Zoology, University of the Punjab , Lahore , Pakistan.
University of the Punjab · PKNational Guard Health Affairs · SAUniversity of Lahore · PKBalochistan University of Information Technology, Engineering and Management Sciences · PKCentre of Excellence in Molecular Biology · PKKing Abdulaziz Medical City · SAKing Abdulaziz University · SAKing Khalid University Hospital · SARashid Latif Medical College · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BCR-ABL kinase domain (K

Indexed as

AdolescentAdultAntineoplastic AgentsChildDisease-Free SurvivalDisease ProgressionDNA Mutational AnalysisDrug Resistance, NeoplasmFemaleFollow-Up StudiesFusion Proteins, bcr-ablHumansImatinib MesylateKaplan-Meier EstimateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleAntineoplastic AgentsBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablImatinib MesylateProtein Kinase InhibitorsBCR-ABLchronic myeloid leukemiacompound mutationsdisease progressionlate chronic phase

Identifiers

PMID28278078
PMCPMC5450736
OpenAlexW2589520961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.